Evaluation of the XIENCE PRIME LL and XIENCE Nano Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions.

Trial Profile

Evaluation of the XIENCE PRIME LL and XIENCE Nano Everolimus Eluting Coronary Stent Coronary Stents, Performance, and Technique in Chronic Total Occlusions.

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 07 Apr 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms EXPERT CTO
  • Sponsors Abbott Laboratories
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 31 Mar 2014 Results after 1-year follow-up presented at the 63rd Annual Scientific Session of the American College of Cardiology.
    • 18 Mar 2013 Planned End Date changed from 1 May 2017 to 1 Feb 2018 as reported by ClinialTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top